Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates

Jarrar, Yazun; Lee, Su-Jun

doi:10.3390/jpm12010104

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, knowledge and educational background about PGx becomes more crucial as the demand towards PGx and personalized medicine in the UAE is becoming more noticeable. 50 Recently, a focus group discussion was conducted on pharmacists working in the UAE. The study outcome recommended several key factors that were concluded from the discussion with the pharmacists.…”

Section: Knowledge and Attitudes Of Physicians And Pharmacists Toward...mentioning

confidence: 99%

A review of pharmacogenomics studies assessing the knowledge and attitudes of physicians and pharmacists across the Arab and Middle Eastern Region

Khattab,

Baguneid,

Ali

et al. 2023

PHARMPRACT

View full text Add to dashboard Cite

The principal goal of pharmacogenomics (PGx) is to achieve the highest drug efficacy while maintaining a low toxicity profile. Historically, health care systems used to target treatment for all individuals with the same diagnosis using a standardized medication or dose that fits all. However, a recent pattern in medicine has emerged focusing on personalized and precision medicine. For effective implementation of PGx, there is a need for more collaborations between all the stakeholders in the healthcare system to integrate the pharmacogenetics concept into practice. When it comes to the knowledge and attitudes towards pharmacogenomics, the majority of medical professionals, including pharmacists and physicians, appear to lack appropriate knowledge and training. Across the Middle East and Arab Region, only few studies have addressed this topic. The current review objective is to shed light on pharmacists' and physicians' knowledge and attitudes towards PGx practice in the UAE, Arab and the Middle East region as compared to the rest of the world. Moreover, highlighting the role of the pharmacists in the application of PGx services and the educational challenges that are faced. Proposed solutions to improve the knowledge gaps will also be discussed. We also aim to provide the international readers as well as the local researchers with a summary of the trends and distribution of the results across these countries.

show abstract

Section: Knowledge and Attitudes Of Physicians And Pharmacists Toward...mentioning

confidence: 99%

A review of pharmacogenomics studies assessing the knowledge and attitudes of physicians and pharmacists across the Arab and Middle Eastern Region

Khattab,

Baguneid,

Ali

et al. 2023

PHARMPRACT

View full text Add to dashboard Cite

show abstract

“…Several factors have been implicated in justifying this practical resistance [ 18 ]. These include knowledge lagging behind a positive attitude for practice by healthcare professionals, high cost, lack of standardized guidelines, and the yet-to-be addressed ethical and social implications [ 11 , 19 , 20 ]. For instance, CPIC explicitly states that its published guidelines are only designed to help practitioners “understand how available genetic test results should be used to optimize drug therapy, rather than whether the tests should be ordered.” [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature

Alzoubi,

Shirazi,

Alrawashdeh

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Precision oncology and pharmacogenomics (PGx) intersect in their overarching goal to institute the right treatment for the right patient. However, the translation of these innovations into clinical practice is still lagging behind. Therefore, this study aimed to analyze the current state of research and to predict the future directions of applied PGx in the field of precision oncology as represented by the targeted therapy class of tyrosine kinase inhibitors (TKIs). Advanced bibliometric and scientometric analyses of the literature were performed. The Scopus database was used for the search, and articles published between 2001 and 2023 were extracted. Information about productivity, citations, cluster analysis, keyword co-occurrence, trend topics, and thematic evolution were generated. A total of 448 research articles were included in this analysis. A burst of scholarly activity in the field was noted by the year 2005, peaking in 2017, followed by a remarkable decline to date. Research in the field was hallmarked by consistent and impactful international collaboration, with the US leading in terms of most prolific country, institutions, and total link strength. Thematic evolution in the field points in the direction of more specialized studies on applied pharmacokinetics of available and novel TKIs, particularly for the treatment of lung and breast cancers. Our results delineate a significant advancement in the field of PGx in precision oncology. Notwithstanding the practical challenges to these applications at the point of care, further research, standardization, infrastructure development, and informed policymaking are urgently needed to ensure widespread adoption of PGx.

show abstract

Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon

El-Gowilly,

Metwaly,

Makhlouf

et al. 2024

Pharmacogenomics

View full text Add to dashboard Cite

Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates

Abstract: The application of personalized medicine (PM) is rapidly evolving [...]

Cited by 5 publications

References 16 publications

A review of pharmacogenomics studies assessing the knowledge and attitudes of physicians and pharmacists across the Arab and Middle Eastern Region

A review of pharmacogenomics studies assessing the knowledge and attitudes of physicians and pharmacists across the Arab and Middle Eastern Region

The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature

Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon

Contact Info

Product

Resources

About